Literature DB >> 24900041

Diagnostic Criteria on (18)F-FDG PET/CT for Differentiating Benign from Malignant Focal Hypermetabolic Lesions of Parotid Gland.

Soo Bin Park1, Joon Young Choi1, Eun Jeong Lee1, Jang Yoo1, Miju Cheon1, Suk Kyong Cho1, Yearn Seong Choe1, Kyung-Han Lee1, Byung-Tae Kim1.   

Abstract

PURPOSE: We investigated PET/CT diagnostic criteria for differentiating benign from malignant parotid lesions with focal (18)F-FDG uptake.
METHODS: The subjects of the study were 272 patients who exhibited focal (18)F-FDG uptake of the parotid gland. Sixty-eight pathologically confirmed parotid lesions from 67 patients were included. The maximum SUV (SUVmax), uptake patterns (homogeneous vs. heterogeneous), size measured by CT, maximum Hounsfield units (HUmax) and margins on CT (well vs. ill defined) of each parotid lesion on PET/CT images were compared with final diagnoses.
RESULTS: Thirty-two parotid lesions were histologically proven to be malignant. There were significant differences in uptake patterns (cancer incidence, heterogeneous:homogeneous = 79.2%:29.5%, p < 0.0001) and margins on CT (cancer incidence, ill:well defined = 84.4%:13.3%, p < 0.0001) between benign and malignant lesions. The cancer risks of parotid lesions were 89.5% with heterogeneous uptake and ill-defined margins, 70.6% with heterogeneous uptake or ill-defined margins (no overlap in subjects) and 9.3% with homogeneous uptake and well-defined margins (p < 0.0001). When any lesion with heterogeneous uptake or ill-defined margins was regarded as malignant, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 90.6% (29/32), 80.6% (29/36), 80.6% (29/36), 90.6% (29/32) and 85.6% (58/68), respectively. For predicting malignancy, combined PET/CT criteria showed better sensitivity, NPV and accuracy than PET-only criteria, and had a tendency to have more accurate results than CT-only criteria. There were no significant differences in SUVmax, size or HUmax between benign and malignant lesions.
CONCLUSION: Uptake patterns and margins on CT are useful PET/CT diagnostic criteria for differentiating benign from malignant lesions.

Entities:  

Keywords:  Cancer; F-FDG; PET; PET/CT; Parotid gland

Year:  2012        PMID: 24900041      PMCID: PMC4042991          DOI: 10.1007/s13139-012-0135-y

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  15 in total

1.  Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors.

Authors:  Yoshitaka Uchida; Satoshi Minoshima; Tetsuya Kawata; Ken Motoori; Koichi Nakano; Toshiki Kazama; Takashi Uno; Yoshitaka Okamoto; Hisao Ito
Journal:  Clin Nucl Med       Date:  2005-03       Impact factor: 7.794

2.  Parotid gland tumors: histologic reevaluation and reclassification of 478 cases.

Authors:  J E van der Wal; H Leverstein; G B Snow; H A Kraaijenhagen; I van der Waal
Journal:  Head Neck       Date:  1998-05       Impact factor: 3.147

3.  Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders.

Authors:  Sandip Basu; Thomas C Kwee; Robert Gatenby; Babak Saboury; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236

4.  Retrospective review: usefulness of a number of imaging modalities including CT, MRI, technetium-99m pertechnetate scintigraphy, gallium-67 scintigraphy and F-18-FDG PET in the differentiation of benign from malignant parotid masses.

Authors:  Nozomi Ozawa; Terue Okamura; Koichi Koyama; Keiko Nakayama; Joji Kawabe; Susumu Shiomi; Hideo Yamane; Yuichi Inoue
Journal:  Radiat Med       Date:  2006-01

5.  Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.

Authors:  Florent Tixier; Catherine Cheze Le Rest; Mathieu Hatt; Nidal Albarghach; Olivier Pradier; Jean-Philippe Metges; Laurent Corcos; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

6.  Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.

Authors:  Joon Young Choi; Kyung Soo Lee; O Jung Kwon; Young Mog Shim; Chung-Hwan Baek; Keunchil Park; Kyung-Han Lee; Byung-Tae Kim
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

7.  Correlation of fine needle aspiration biopsy and CT scanning of parotid masses.

Authors:  H M Berg; J B Jacobs; D Kaufman; D L Reede
Journal:  Laryngoscope       Date:  1986-12       Impact factor: 3.325

8.  Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions.

Authors:  T Okamura; J Kawabe; K Koyama; H Ochi; R Yamada; H Sakamoto; M Matsuda; Y Ohashi; Y Nakai
Journal:  Acta Otolaryngol Suppl       Date:  1998

9.  Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses.

Authors:  D Rubello; C Nanni; P Castellucci; L Rampin; M Farsad; R Franchi; G Mariani; G Menaldo; S Fanti
Journal:  Panminerva Med       Date:  2005-09       Impact factor: 5.197

Review 10.  Salivary gland tumours.

Authors:  P M Speight; A W Barrett
Journal:  Oral Dis       Date:  2002-09       Impact factor: 3.511

View more
  5 in total

1.  Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?

Authors:  Ayse Tuba Karagulle Kendi; Kelly R Magliocca; Amanda Corey; James R Galt; Jeffrey Switchenko; J Trad Wadsworth; Mark W El-Deiry; David M Schuster; Nabil F Saba; Patricia A Hudgins
Journal:  AJR Am J Roentgenol       Date:  2016-06-08       Impact factor: 3.959

2.  Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis.

Authors:  Giorgio Treglia; Francesco Bertagna; Ramin Sadeghi; Barbara Muoio; Luca Giovanella
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-28       Impact factor: 2.503

3.  The Value of F-18 FDG PET for Planning Treatment and Detecting Recurrence in Malignant Salivary Gland Tumors: Comparison with Conventional Imaging Studies.

Authors:  Hye Lim Park; Ie Ryung Yoo; Narae Lee; Hyukjin Yoon; Eun Kyoung Choi; Hyun Su Choi; Sung Hoon Kim
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

4.  Predictors of pathologic outcome of focal FDG uptake in the parotid gland identified on whole-body FDG PET imaging.

Authors:  Marc C Mabray; Spencer C Behr; David M Naeger; Robert R Flavell; Christine M Glastonbury
Journal:  Clin Imaging       Date:  2015-07-16       Impact factor: 1.605

Review 5.  Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT.

Authors:  Deborah Pencharz; Malavika Nathan; Thomas L Wagner
Journal:  Br J Radiol       Date:  2018-01-31       Impact factor: 3.039

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.